We are international
Donate
• about myeloma TEXT SIZE   
diagnosis & staging    back

International Myeloma Working Group Guidelines on Imaging Techniques in the Diagnosis and Monitoring of Multiple Myeloma1
03.01.10

Up to 90% of myeloma patients develop osteolytic lesions, a major cause of morbidity and mortality, during the course of their disease. 2  Appropriate use of imaging techniques is essential to identify and characterize skeletal complications resulting from MM, to determine the extent of intramedullary and extramedullary foci, and to evaluate disease progression.

Several imaging techniques are used to clarify bone and soft tissue disease in the diagnosis and management of myeloma: conventional radiography, computed tomography (CT), magnetic resonance imaging (MRI), and nuclear medicine imaging. The following International Myeloma Working Group (IMWG) guidelines provide recommendations for the use of each of the technologies. The appropriate use of these various technologies for each individual patient should be discussed directly with the treating physician.

  1. CONVENTIONAL RADIOGRAPHY
  • Conventional radiography is still considered the "gold standard" for the determination of the extent of MM bone disease at diagnosis.
  • In a complete skeletal survey, it is important to include all areas of possible myeloma involvement: cervical, thoracic, and lumbar spine; skull, chest, pelvis, humeri, and femora.
  • Conventional radiography reveals lytic disease only when over 30% of the trabecular bone has been lost. This and other limitations of conventional radiology are listed in Table 1.

Table 1: Conventional Radiology: Limitations

  • Some areas not well visualized
  • Limited sensitivity: 10-20% of lesions/abnormalities missed
  • Reduced specificity vs. benign causes of osteopenia (e.g. steroids/post-menopausal)
  • Observer dependent
  • Time/Tolerance for standard survey not ideal
  • Usually fail to show response to treatment
  1. COMPUTED TOMOGRAPHY
  • CT scanning allows excellent 3D reconstruction of images.
  • In some institutions, CT scanning has replaced conventional radiography as the initial imaging tool used in patients with disease related problems of the spine or pelvis.
  • Advantages of CT are detailed in Table 2.

Table 2: Advantages of Computed Tomography (CT)

  • Detects small osteolytic lesions
  • Faster than standard radiographic survey
  • Provides 3D reconstruction of images
  • Shows associated soft tissue disease
  • Greater sensitivity and specificity versus standard radiography
  • Allows estimation of fracture risk
  • Excellent for radiotherapy planning and for surgical intervention
  • A negative point is that the radiation dose with CT is 1.3-3 times higher than that delivered during standard radiography.
  1. MAGNETIC RESONANCE IMAGING
  • MRI allows visualization of the medullary cavity and a direct assessment of the degree of MM cell infiltration before bone destruction becomes visible on plain radiographs, without radiation exposure.
  • MRI can be used for the accurate illustration of the vertebral fracture or the percentage of loss of vertebral height before vertebroplasty or kyphoplasty.
  • Whole-body MRI is superior to whole-body MDCT, a very sensitive CT methodology.
  • MRI is useful in determining prognosis based on the number, size,  and pattern of MR bone marrow lesions.
  • For a list of other advantages of MRI in myeloma, see Table 3.

Table 3: Role of Magnetic Resonance Imaging (MRI)

  • More sensitive than standard radiography
  • Excellent imaging of axial skeleton
  • Discriminates myeloma vs. normal marrow
  • Excellent diagnostic discrimination for spinal cord/nerve compression issues, as well as soft tissue disease
  • Can detect avascular necrosis of the femoral head
  • Can detect amyloid/light chain deposits in the heart and other sites
  • Can be used to assess disease status in MGUS, asymptomatic myeloma and for solitary plasmacytomata of bone
  • Can be used to monitor response (although improvements can be delayed)
  • Caveats:
    • A question was raised at the ASH meeting in December, 2009, regarding the use of gadolinium enhancement in MRI in light of its promotion of myeloma cell growth in vitro. 4
    • The main methodological consideration with MRI imaging is the lack of specificity of the findings.
    • MRI must be performed at least one month after G-CSF administration;  diffuse or focal marrow changes after treatment with G-CSF cannot be easily distinguished from active disease.
    • Contraindications to MRI include patient intolerance, cardiac pacemakers, and intra-orbital foreign bodies
  1. NUCLEAR MEDICINE IMAGING

Technetium bone scintigraphy

  • The specificity and sensitivity of technetium bone scintigraphy at the time of initial diagnosis, in follow-up studies, and in the evaluation of bone pain is lower compared to conventional radiography.
  • Technetium bone scintigraphy is related mainly to osteoblastic process. Since myeloma is characterized by osteoblast dysfunction, bone scintigrapy is not recommended for the assessment of myelomatous bone disease.

99mTc-sestamibi

  • 99mTc-sestamibi (MIBI) imaging closely reflects myeloma disease activity in bone marrow with very high sensitivity and specificity.5,6
  • MIBI is not useful in MGUS work-up, since it is always negative and cannot be used to predict MGUS transformation.
  • MIBI scanning has inferior value compared to FDG-PET/CT, and is inferior to MRI in assessing the extent of myelomatous bone marrow infiltration in the spine.
  • MIBI score is significantly related to ISS, bone marrow biopsy infiltration rate, and serum B2M.
  • MIBI washout may predict for response to conventional or high-dose chemotherapy.
  • MIBI scan was of prognostic value in ISS stage II MM patients, but added no relevant information to ISS in patients with stages I and III.
  • MIBI cannot detect ONJ (osteonecrosis of the jaw) in myeloma patients.

Postiron emission tomography (PET)

  • Subcentimeter lytic lesions seen on plain radiograph may not be detectable on PET scanning.
  • Fusion scanning combining both PET and CT addresses the issue of limited spatial resolution and takes less time than (approximately 30 minutes) than a PET scan alone (approximately one hour).
  • PET/CT allows identification of high-risk myeloma and can be used to monitor non-secretory myeloma as well as patients in CR without measurable M-component.
  • PET/CT studies are more sensitive than other imaging modalities for localizing extramedullary disease; they reveal additional lesions in almost 30% of patients who had been diagnosed with solitary plasmacytoma by MRI.
  • In 30% of newly diagnosed patients, PET/CT scans of the spine and pelvis failed to show abnormal findings in areas in which MRI revealed an abnormal pattern of bone involvement.
  • Combining PET/CT with MRI of the spine and pelvis increases the ability to detect sites of active MM, both medullary and extramedullary.
  • PET/CT has false positive results, particularly in areas of inflammation or infection.
  • PET/CT is more sensitive than MRI for making the diagnosis of mandibular osteonecrosis.
  • Further studies are needed before the use of PET as a standard tool in both diagnosis and follow-up of MM is recommended.
  • The use of MIBI PET should particularly be considered in the evaluation of a patient with an early-stage MM to exclude the presence of more extensive disease.

Dual-energy X-ray absorptiometry (DEXA)

  • DEXA may influence the decision to begin bisphosphonate treatment.
  • DEXA is a quick, noninvasive investigation that uses a small dose of radiation.
  • Its use is limited by spinal disease and the difficulty of distinguishing myeloma osteoporosis from malignant osteoporosis.
  • Sequential DEXA-scans are not recommended because they show heterogeneous local BMD changes, and cannot predict disease progression.

1Dimopoulos MA et al.International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma, Leukemia (2009), 1-12.

2Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol 2005: 16: 1223-1231.

3Bauer-Melnyk A et al. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. AJR Am J Roentgenol 2008; 190: 1097-1104.

4Fulciniti M et al. Gadolinium Containing Contrast Agent Promotes Multiple Myeloma Cell Growth: Implication for Clinical Use of MRI in Myeloma. ASH abstract 1809, 51st annual ASH meeting, poster session on Biology and Pathophysiology of Myeloma

5Balleari E et al. Technetium-99-sestaMIBI scintigraphy in multiple myeloma and related gammopathies: a useful tool for the identification and follow-up of myeloma bone disease. Haematologica 2001; 86: 78-84.

6Tiravola EB et al. The use of 99m-Tc-MIBI scanning in multiple myeloma. Br J Cancer 1996; 74: 1815-1820.


 related videos
 related articles
IMWG consensus state...
IMWG Guidelines for ...
IMWG Guidelines for ...
IMWG Guidelines for ...
IMWG Guidelines for ...
International Myelom...
IMWG Criteria for th...
A Practical Guide to...
ASCO 2010: A phase I...
ASCO 2010: Bone mark...
ASCO 2010: Elotuzuma...
ASCO 2010: Lenalidom...
ASCO 2010: Mechanism...
ASCO 2010: Modified ...
ASCO 2010: Multiple ...
ASCO 2010: Neurotoxi...
ASCO 2010: Phase I s...
ASCO 2010: Phase Ib ...
ASCO 2010: Results o...
ASCO 2010: Stromal e...
ASCO 2010: Total the...
Clinically relevant ...
Confirmation of the ...
Developing a SNP Cla...
Eliminating the comp...
ESAs not the culprit...
Genetic association ...
Genetic Associations...
Genetic Associations...
Genetic polymorphism...
Genetic Variations A...
Genomic variation in...
Inaugural Summit of ...
International Myelom...
Long-Term Follow-Up ...
Long-Term Follow-Up ...
New Approaches to Tr...
Oncology Nurses Take...
Osteonecrosis of the...
RT-PCR Amplicons in ...
Survival and Years o...
Use of Bisphosphonat...

Common Symptoms Of M...
Statement on the pas...
Advocacy Update - Se...
Advocacy Update - Se...

ASCO 2010: A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM).
ASCO 2010: Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma.
ASCO 2010: Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
ASCO 2010: Lenalidomide maintenance after transplantation for myeloma.
ASCO 2010: Mechanism of the antimyeloma activity of PU-H71, a novel purine scaffold HSP90 inhibitor.
ASCO 2010: Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment of AL amyloidosis (AL) and/or high-risk myeloma (hM): Analysis of a Southwest Oncology Group trial.
ASCO 2010: Multiple myeloma is characterized by widespread epigenomic alterations with prognostic implications.
ASCO 2010: Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM).
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
ASCO 2010: Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).
ASCO 2010: Stromal elements and engraftment (ENG) in autologous hematopoietic progenitor cell transplant (autoHCT) for myeloma.
ASCO 2010: Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing of maintenance components dexamethasone (D), thalidomide (T) and bortezomib (V).
What is multiple myeloma?
Dr. Morie Gertz of the Mayo Clinic in Rochester, MN.
IMWG consensus statement on the role of vertebral augmentation in multiple myeloma
IMWG Guidelines for Facilities and Services for the Management of Myeloma Patients
IMWG Guidelines for the Management of Multiple Myeloma Patients Ineligible for Standard High-Dose Chemotherapy with Autologous Stem Cell Transplantation
IMWG Guidelines for the Prevention of Thalidomide- and Lenalidomide-Associated Thrombosis in Myeloma
IMWG Guidelines for the Use of Bisphosphonates in Myeloma
International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma
IMWG Criteria for the Diagnosis of Myeloma and Guidelines for the Diagnostic Work-Up of Myeloma
A Practical Guide to Achieving and Maintaining the Best Response to Lenalidomide in Multiple Myeloma: Roundtable Proceedings
ASCO 2010: A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM).
ASCO 2010: Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma.
ASCO 2010: Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
ASCO 2010: Lenalidomide maintenance after transplantation for myeloma.
ASCO 2010: Mechanism of the antimyeloma activity of PU-H71, a novel purine scaffold HSP90 inhibitor.
ASCO 2010: Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment of AL amyloidosis (AL) and/or high-risk myeloma (hM): Analysis of a Southwest Oncology Group trial.
ASCO 2010: Multiple myeloma is characterized by widespread epigenomic alterations with prognostic implications.
ASCO 2010: Neurotoxic and peripheral neuropathic effects in preclinical and clinical studies of carfilzomib (CFZ), a novel proteasome inhibitor (PI).
ASCO 2010: Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM).
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
ASCO 2010: Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).
ASCO 2010: Stromal elements and engraftment (ENG) in autologous hematopoietic progenitor cell transplant (autoHCT) for myeloma.
ASCO 2010: Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing of maintenance components dexamethasone (D), thalidomide (T) and bortezomib (V).
Clinically relevant end points and new drug approvals for myeloma
Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma
Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients
Eliminating the complete response penalty from myeloma response criteria
ESAs not the culprit: More studies required
Genetic association with thalidomide mediated venous thrombotic events in myeloma indentified using targeted genotyping
Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma
Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma
Genetic polymorphisms of EPHX1, Gsk3 beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma
Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations
Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival
Inaugural Summit of the International Myeloma Working Group Lays the Groundwork for a Course Toward a Cure.
International Myeloma Working Group at ASH 2009
Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences
Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences
New Approaches to Treatment for Multiple Myeloma: Durable Remission and Quality of Life as Primary Goals
Oncology Nurses Take the Lead in Providing Novel Therapy Guidelines for Multiple Myeloma
Osteonecrosis of the Jaw and Biphosphonates
RT-PCR Amplicons in the Plasma of Multiple Myeloma Patients
Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma
Use of Bisphosphonates in Multiple Myeloma: IMGW Response to Mayo Clinic Consensus Statement
WHAT IS MULTIPLE MYELOMA
Common Symptoms Of Multiple Myeloma
Statement on the passing of Senator Kennedy
Advocacy Update - September 1, 2009
Advocacy Update - September 15, 2009